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Abstract
Background: Covalent histone modifications are central to all DNA-dependent processes. Modifications of histones
H3 and H4 are becoming well characterised, but knowledge of how H2A modifications regulate chromatin
dynamics and gene expression is still very limited.
Results: To understand the function of H2A modifications, we performed a systematic analysis of the histone H2A
methylation status. We identified and functionally characterised two new methylation sites in H2A: R11 (H2AR11)
and R29 (H2AR29). Using an unbiased biochemical approach in combination with candidate assays we showed
that protein arginine methyltransferase (PRMT) 1 and PRMT6 are unique in their ability to catalyse these
modifications. Importantly we found that H2AR29me2 is specifically enriched at genes repressed by PRMT6,
implicating H2AR29me2 in transcriptional repression.
Conclusions: Our data establishes R11 and R29 as new arginine methylation sites in H2A. We identified the
specific modifying enzymes involved, and uncovered a novel functional role of H2AR29me2 in gene silencing in
vivo. Thus this work reveals novel insights into the function of H2A methylation and in the mechanisms of PRMT6-
mediated transcriptional repression.
Background
Post-translational modifications of histones play an
important role in the regulation of all nuclear processes
occurring on chromatin. Depending on the type of mod-
ification and/or the residue modified, they can be
involved in gene activation or silencing. In particular the
methylation of histones, has been extensively studied,
and has been shown to regulate both processes [1]. His-
tones can be methylated on lysine residues by lysine
methyl transferases (KMTs) and on arginine residues by
protein arginine methyl transferases (PRMTs). Of the
four core histones (H3, H2B, H2A and H4), methylation
of the N-terminal tails of H3 and H4 has been inten-
sively studied, whereas very little is known about modifi-
cations of H2A and H2B.
Several potential methylation sites in H2A have been
identified by mass spectrometry (MS) analysis, including
the presence of at least two methyl groups in the first
17 amino acids of H2A [2]. However, the only methyla-
tion site of H2A that has been experimentally studied is
methylation of arginine 3 (H2AR3) [3].
PRMTs are involved in a variety of cellular processes
[4-6], and have recently been linked with carcinogen-
esis [7]. Multiple PRMTs have been described to date
[8], all of which share a set of conserved sequence
motifs (I, post-I, II and III) and a THW (threonine-his-
tidine-tryptophan) loop, but differ in the composition
of their protein domain and in their cellular localisa-
tion. All PRMTs can catalyse monomethylation of argi-
nines (MMA), and are divided in two families
according to their dimethylation activity: type I
enzymes catalyse asymmetric dimethylation (aDMA),
whereas type II enzymes perform symmetric dimethy-
lation (sDMA), [4,5,9]. Of the type I enzymes, PRMT1
methylates R3 in H4 and H2A in vitro [3], and PRMT4
methylates H3 on R2, R17 and R26 [10]. However, the
main PRMT able to methylate H3R2 in vivo is PRMT6
[11,12], and PRMT6 can also methylate H4 and H2A
in vitro [11]. Of the type II PRMTs, PRMT5
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PRMT7 catalyses monomethylation of histones in
vitro, but the specific arginines targeted remain uni-
dentified [13,14]. Recently, PRMT2 has been shown to
methylate histones H4 and/or H3 [15,16]. For PRMT3,
PRMT8 and PRMT9, no histone substrates have been
described yet.
Modifications of histone H2A and the role of the H2A
N-terminal tail itself in nucleosome biology are not fully
understood. Because of this, we aimed to identify and
characterise new methylation sites within H2A and their
effectors. In this study, we identified H2AR11 and
H2AR29 as novel arginine methylation sites, and showed
that these modifications are set in vitro by the enzymes
PRMT1 and PRMT6. To understand the function of
H2AR29 methylation, we raised an H2AR29me2-specific
antibody, and found that this marker is indeed in vivo
catalysed by PRMT6. We found that H2AR29me2 is
enriched on genes repressed by PRMT6, establishing
H2AR29me2 as a novel repressive player involved in
PRMT6 function.
Results
The knowledge of H2A modifications is still very lim-
ited, and the characterisation of novel histone markers
is fundamental to understand how post-translational
modifications can regulate gene expression. H2AR3 is
the only methylation site on this histone characterised
to date [3,17], therefore we were interested in identify-
ing novel H2A methylation sites, the modifying enzymes
and their function.
Endogenous PRMT1 can methylate H2A
We followed an open and unbiased approach to identify
histone methyltransferases that specifically methylate
histone H2A. We established a biochemical fractionation
protocol to purify these enzymes from nucleosolic HeLa
cell extract (Figure 1A). To distinguish between H2AR3
methylation and methylation of other sites, we used N-
terminally truncated H2A (H2A 4-129) as a substrate in
our assays.
In the fractions eluted from the heparin-Sepharose
column, we detected activities able to methylate
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Figure 1 H2A is methylated by protein arginine methyltransferase (PRMT)1 at novel sites. (A) Biochemical purification scheme (for details
see Additional file 5, supplementary materials and methods) of H2A-specific histone methyltransferase from HeLa nuclear extract. (B) (Upper
panel) Silver stain of heparin-Sepharose fractions 1 to 8. PRMT1 was identified by mass spectrometry (asterisk) (see Additional file 1, Figure S 1).
Autoradiography of histone methyltransferase assays of indicated heparin-Sepharose fractions using (middle panel) H2A 4-129 and (lower panel)
endogenous acidic extracted histones, full-length recombinant H2A, myelin basic protein (MBP), and glutathione S-transferase (GST)-GAR (glycine-
and arginine-rich) as substrates.
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mers, myelin basic protein (MBP), GAR (glycine- and
arginine-rich) motifs (a generic substrate for PRMTs)
(Figure 1B, lower panel), and most importantly, H2A 4-
129 (Figure 1B, middle panel). MS analyses determined
this activity as PRMT1 (Figure 1B, asterisk; see Addi-
tional file 1, Figure S1). Taken together, these results
show that PRMTs, in particular PRMT1, can methylate
H2A on sites other than R3.
PRMT1 and 6 methylate H2A on R11 and R29 in vitro
Given the overlapping target specificities displayed by
some PRMT family members, we next addressed whether
other PRMTs can methylate H2A. For this, we established
HEK293 cell lines stably expressing Flag-hemagglutinin
( H A )f u s i o n so fP R M T 1 ,2 ,3 ,5 ,6 ,7a n d8 ,a n du s e d
immunoprecipitated PRMTs in our HMT assays (Figure
2A). Because PRMT4 is the best-studied PRMT and has
been shown to methylate H3 only, we omitted it from our
studies. We checked that the tagged PRMT1, 2, 3, 5, 6, 7,
8 were expressed (see Additional file 2, Figure S2A) and
displayed the expected pattern of cellular distribution (see
Additional file 2, Figure S2B). In addition we also verified
that the immunoprecipitated PRMTs were active in our
assays as shown by their ability to modify MBP (see Addi-
tional file 2, Figure S2C). In accordance with previous
reports [18], PRMT2 showed no activity (Figure 2A; see
Additional file 2, Figure S2C) in our assays, whereas
PRMT1, 3, 5, 6, 7 and 8 could methylate recombinant
H2A (Figure 2A, lane 3), but only PRMT1, 5 and 6 could
also methylate H2A in octamers (Figure 2A, lane 2). We
excluded PRMT7 and 8 from further investigations,
because they co-immunoprecipitated with endogenous
PRMT1 (data not shown), making it difficult to distinguish
between their activities and those of PRMT1.
Next, we wanted to determine whether PRMT1, 3, 5
and 6 can methylate sites other than H2AR3. Impor-
tantly, we found that only PRMT1 and 6 (not PRMT3
and 5) had significant activity on H2A 4-129 (Figure
2B). To investigate which arginines can be methylated
by these enzymes, we used H2A 4-129 with point muta-
tions in different arginines in our HMT assays. For
PRMT1, only background activity was detectable on a
R11K (H2A4-129 R11K) mutant, indicating that it pre-
ferentially methylates H2AR11 (Figure 2C, left panel).
For PRMT6 we saw a reduction in the methylation
activity on a R11K mutant, but not a complete loss of
the signal (Figure 2C, right panel), whereas on a
R11KR29K (H2A4-129 R11KR29K) double mutant, only
background activity was detectable, showing that in our
HMT assays PRMT6 can methylate both H2AR11 and
H2AR29.
To confirm these results on full-length H2A, we per-
formed MS analysis after in vitro methylation by
PRMT1 and 6. We found that PRMT1 does indeed
methylate H2AR11 (Figure 2D), and that PRMT6
methylates H2AR29 (Figure 2E).
H2AR29me2 is enriched on genes repressed by PRMT6
To gain insight in the function of H2A methylation in
vivo, we raised antibodies against asymmetrically
dimethylated H2AR11 and H2AR29. We succeeded in
generating a specific antibody that passed our rigorous
quality testing for H2AR29me2 only (see Additional file
3, Figure S3A-D). Using this antibody, we detected
H2AR29me2 in various human and mouse cell lines
(Figure 3A). We also verified the presence of
H2AR29me2 in vivo by MS analysis (Figure 3B; see
Additional file 4, Figure S4A-C). To confirm that
PRMT6 is indeed the enzyme responsible for
H2AR29me2 in vivo, we used both a loss-of-function
and a gain-of-function approach in HEK293 cells. Stable
small hairpin RNA interference (RNAi)-mediated knock-
down of PRMT6 (but not of PRMT1) resulted in a
decrease in H2AR29me2 levels by approximately 50%
(Figure 3C, left panel), whereas overexpression of
PRMT6 increased H2AR29me2 levels by approximately
2.5 times (Figure 3C, right panel), clearly demonstrating
the ability of PRMT6 to methylate H2AR29 in vivo.
To investigate the distribution H2AR29me2 in bulk
chromatin, we performed a time course of micrococcal
nuclease digestion of chromatin. Accessible chromatin
enriched in active markers (H3K4me3, H2AK9Ac) is
released in the early fractions, whereas condensed chro-
matin enriched in repressive markers (H3K9me3,
H4K20me3) is only released at later time points. We
detected H2AR29me2 enriched in the later fractions
(Figure 4A), suggesting that it localises preferentially to
transcriptionally inactive chromatin.
To determine whether H2AR29me2 has a function in
PRMT6-dependent transcriptional regulation, we investi-
gated whether H2AR29me2 is enriched at specific genes.
Recently, by performing an expression profile after
PRMT6 RNAi, PRMT6-regulated genes were identified
[19], and we therefore concentrated on these genes. Of
the genes tested, a subset (for example, HMOX1,
ANTRX2, ISG20, LPNX) became upregulated upon
PRMT6 overexpression (Figure 4B), suggesting an acti-
vating role of PRMT6 at these loci, whereas other genes
(for example, EIF1B, ATP5G1, TMEM158, UROD) were
(moderately) downregulated (Figure 4B). Several genes
that did not react to PRMT6 overexpression have been
described to be repressed by PRMT6 [19], but are actu-
ally transciptionally silent. Their mRNA was shown to be
below the detection limit [20] (Figure 4B, cross).
Next we performed chromatin immunoprecipitation
(ChIP) assays using our H2AR29me2-specific antibody.
Interestingly, we found that H2AR29me2 was enriched
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Figure 2 Protein arginine methyltransferase (PRMT)1, 5 and 6 can methylate recombinant and endogenous H2A. (A) Histone
methyltransferase (HMT) assays with different Flag-hemagglutinin (HA)-tagged PRMTs immunoprecipitated from HEK 293, stably expressing
PRMTs on (lane 1) nucleosomes, (lane 2) purified histones and (lane 3) recombinant full-length H2A. (Left) Coomassie stain and (right)
autoradiography are shown. (B) HMT assays using recombinant full-length H2A and H2A 4-129. Only PRMT1 and 6 were found to methylate H2A
4-129. (C) HMT assays (left panel) with Flag-Ha-PRMT1 on H2A 4-129, H2A 4-129 R11 mutated to K, and (right panel) with Flag-Ha-PRMT6 on
H2A 4-129, H2A 4-129 R11K, H2AR11K R29K. Loading controls are shown below. (D) Mass spectrometry (MS) analysis of H2 Amethylated in vitro
by PRMT1 shows methylation of R11. Tandem MS (MS/MS) spectra of a propionylated histone H2A peptide at a mass:charge ratio (m/z) of 876
from trypsin digest of propionylated H2A is shown. (E) MS analysis of H2A, in vitro methylated by PRMT6 shows methylation of R29. MS/MS
spectrum of a doubly-charged peptide ion at m/z of 703.901 is shown.
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Figure 3 H2AR29 is methylated by protein arginine methyltransferase (PRMT)6 in vitro and in vivo. (A) Immunoblot with H2AR29me2-
specific antibody shows the presence of H2AR29me2 in various human and mouse cell lines. (B) Mass spectrometry (MS) analysis of
endogenous, purified H2A. Shown in the collisionally activated dissociation (CAD) tandem MS (MS/MS) spectrum of the doubly-charged histone
H2A derived tryptic peptide
22AGLQFPVGR(me2)
29 ion (mass:charge ratio (m/z) 486.78522; 0.71 ppm mass deviation), identifying R29 as
dimethylated. The identity and assignment of the b and y ions of the dimethyl arginine-containing peptide was corroborated by nano liquid
chromatography (LC)-MS/MS analysis of the corresponding chemically synthesised peptide (see Additional file 4, Figure S4). (C) (Top panel)
H2AR29me2 levels decreased upon knockdown of PRMT6, but not PRMT1. PRMT1 RNA levels (relative to b-actin) measured by reverse
transcriptase (RT)-PCR in HEK293 cells were reduced by approximately 80%, and PRMT6 by 50%. (Bottom panel) H2AR29me2 levels were not
altered upon knockdown of PRMT1, but they decreased by approximately 50% upon PRMT6 knockdown. The average of the H2AR29me2 levels
relative to the control from three independent experiments is shown; error bars correspond to the standard deviation of the means. (D)
Overexpression of PRMT6 (top panel) in HEK293 cells resulted in increased H2AR29me2. (Top panel) PRMT6 RNA levels (relative to b-actin) were
measured by RT-PCR. (Bottom panel) H2AR29me2 levels increased by approximately 2.5 times in PRMT6 overexpressing cells compared with the
wild-type cells. The average of the H2AR29me2 levels relative to the control from four independent experiments is shown; error bars correspond
to the standard deviation of the means.
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Page 5 of 10on the promoters of genes that where found to be
repressed by PRMT6 (for example, EIF1b, MMP9,
THBS1, TNFRSF11B) (Figure 4C) [19], but we did not
detect any significant enrichment at genes that are acti-
vated by PRMT6 (for example, HMOX1, ANTRX2,
ISG20, LPNX) (Figure 4C). These data clearly implicate
H2AR29me2 as a novel histone modification in
PRMT6-mediated gene repression.
Discussion
The results presented here show that PRMT1 and 6 can
methylate histone H2A at arginine residues other than
H2AR29me2
H4K20me3
H3K9me3
H3K4me3
H2AK9Ac
Ponceau
MNase 2‘ 8‘  4‘ 
Sup
NIH
AB
l
o
g
 
R
N
A
 
l
e
v
e
l
s
 
P
R
M
T
6
/
E
V
 
xx x x
E
F
1
B
M
M
P
9
T
H
B
S
1
T
N
F
R
S
F
1
1
B
M
A
R
C
H
4
A
T
P
5
G
1
T
M
E
M
1
5
8
U
R
O
D
C
T
P
S
M
T
1
X
H
M
O
X
1
A
N
T
X
R
2
I
S
G
2
0
L
P
N
X
C
E
F
1
B
M
M
P
9
T
H
B
S
1
T
N
F
R
S
F
1
1
B
M
A
R
C
H
4
A
T
P
5
G
1
T
M
E
M
1
5
8
U
R
O
D
C
T
P
S
M
T
1
X
H
M
O
X
1
A
N
T
X
R
2
I
S
G
2
0
L
P
N
X
H
2
A
R
2
9
m
e
2
/
g
e
n
e
 
d
e
s
e
r
t
 
0.1
1
10
1
2
3
4
5
6
7
8
9
Figure 4 H2AR29me2 is enriched at genes repressed by protein arginine methyltransferase (PRMT)6. (A) H2AR29me2 was found to be
enriched in less accessible chromatin fractions. Kinetic of micrococcal digestion of chromatin [28]. Kinetic of micrococcal digestion of chromatin
[28] is shown. The abundance of the indicated histones modifications in the fractions was tested by western blotting with specific antibodies. (B)
PRMT6 was overexpressed in HEK293 cells. Expression levels of the indicated genes were measured by real-time PCR and normalized to b-actin.
The relative expression of the normalized genes in control and PRMT6-overexpressing cells was quantified using the ΔCt method, and the
resulting relative quantification (RQ) values were plotted in a bar graph on a logarithmic scale. The cross indicates genes not expressed in
HEK293 (GEO: record GSE11892; [20]). (C) Chromatin immunoprecipitation assay with H2AR29me2 antibody. Purified DNA from
immunoprecipitated chromatin fragments from HEK293 cells was amplified by real-time PCR with specific primer sets for indicated gene
promoters (see Additional file 6, Table S1). The enrichment of precipitated chromatin relative to an intergenic region was determined and
plotted in a bar graph. Error (standard deviation) bars are shown.
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Page 6 of 10the previously described R3. We found that R11 and
R29 in H2A can be methylated and are targeted for
methylation by PRMT1 and 6, respectively. Further-
more, we found that in vivo, H2AR29me2 is enriched at
genes that are repressed, but not at genes activated by
PRMT6, implicating H2AR29me2 as a novel player in
PRMT6-mediated gene repression.
Systematic analysis of PRMTs for H2A specific activity
Currently, very little is known about the methylation
status of H2A and its biological function. The first argi-
nine in H2A, R3, has to date been the only methylation
site characterised in H2A. H2AR3 (and H4R3) is within
a GRG (glycine-arginine-glycine) motif, the consensus
sequence for arginine methylation, explaining the
observed strong activities towards H2AR3 in our in vitro
assays. Recently, it has been shown that PRMT5 methy-
lates cytoplasmic R3 of H2A rather than H4, and that it
might be involved in the repression of differentiation
genes [21]. However, because of the high sequence con-
servation between the extreme N-termini of H2A and
H4, it is very difficult to distinguish between these two
methylation sites in vivo.
We used a biochemical screen to identify H2A-specific
HMTs and novel methylation sites. By applying different
purification schemes, we found PRMT1 but no KMTs
methylating H2A, in line with the fact that no H2A-spe-
cific KMT has been described to date. To investigate
whether more members of the PRMT family can methy-
late H2A, we used PRMTs expressed in mammalian
cells. We found that in vitro, PRMT1 and 6 can methy-
late the truncated form of H2A that lacks R3, showing
that other sites are methylated. Through combined ana-
lysis by MS (Figure 3A, B), point mutants (Figure 3C)
and Edman degradation (data not shown), we identified
two new methylation sites in H2A: R11 and R29.
H2AR11 or H2AR29 are not within a GRG PRMT
consensus sequence; however, arginines surrounded by
small hydrophobic amino acids such as those for
H2AR11 and R29, have also been shown to be good
substrates for PRMTs [22]. To study the function of
H2AR11me2 and H2AR29me2 in vivo, we attempted to
r a i s es p e c i f i ca n t i b o d i e s .A l t h o u g hw ew e r eu n a b l et o
obtain a satisfactory antibody for H2AR11me2, we man-
aged to generate an antibody specific for H2AR29me2.
Therefore we focused our in vivo studies on H2R29me2.
Further studies will be required to determine the func-
tion of the second new methylation site, H2AR11me2.
H2AR29 is a novel PRMT6 target
In S. cerevisiae, H2AR29 is conserved as H2AR30,
however we have so far failed to detect H2AR30
methylation. In mammals, we found that PRMT6 can
methylate H2AR29 in vitro and in vivo.P R M T 6i st h e
primary enzyme responsible for H3R2 methylation
[11,12], but has also been shown to methylate H4 and
H2A at R3 [11]. H3R2 methylation has been well stu-
died, and found to counteract the activating H3K4me3
marker, implicating it in the repression of genes
[11,12,23]. Using an RNAi approach, genes regulated
by PRMT6 were recently identified [19]. We analysed
several of these genes for the presence of the novel
H2AR29me2 marker. We found it to be enriched at
the promoters of genes that were shown to be
repressed by PRMT6, linking H2AR29me2 with tran-
scriptional silencing by PRMT6, and giving novel
insights into the mechanism of PRMT6-mediated gene
repression. Of the H2AR29me2 target genes, throm-
bospondin-1 (THBS1) is of particular interest, being a
potent natural inhibitor of angiogenesis and cell migra-
tion, dysregulated in several types of cancer [24].
Whereas DNA methylation has been shown to regulate
THBS1 expression, the role of histone modifications is
less understood [25], however, PRMT6 was recently
shown to be present at the THBS1 promoter [19]. Our
data suggest that the H2AR29me2 mark set by PRMT6
contributes to the regulation of THBS1 expression.
Due to the lack of ChIP-grade PRMT6 antibodies, we
cannot exclude that these genes are indirect PRMT6
targets; however, our PRMT6 knockdown and overex-
pression data strongly suggest that PRMT6 is the
enzyme methylating H2AR29me2, and puts the marker
at these genes.
In contrast to this repressive function, PRMT6 also
has a function as a coactivator [26]. In line with this, we
found genes that are activated by PRMT6 overexpres-
sion. Interestingly, we did not detect enrichment of
H2AR29me2 on these genes. We therefore suggest that
H2AR29me2 could help to discern the functional output
of PRMT6 activity. Indeed, the ability of PRMT6 to act
as a coactivator might be linked to its activity towards
H4R3 and/or H2AR3 [8], rather than H2AR29. Our
ChIP data, together with the preferential enrichment of
H2AR29me2 in more inaccessible chromatin (Figure
4A), establish this novel marker as a potential key regu-
lator in PRMT6-mediated gene repression.
Conclusions
Our work has identified two new methylation sites in
H2A and the corresponding methyltransferases. Impor-
tantly, we have revealed novel insights into the function
of H2A methylation in vivo and in the mechanisms of
PRMT6-mediated transcriptional repression. For the
future it will be exciting to study further H2A modifica-
tions; however, this will require the development of
novel specific antibodies. To unravel the multiple func-
tions of PRMT6 [26], it will be important to investigate
the mechanisms fine-tuning the activity of PRMT6
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the specific biological pathways involved in the deposi-
tion of H2A methylation markers.
Methods
Cloning of PRMT, H2A constructs and cell lines
PRMTs were cloned in pcDNA3.1 containing one Flag
and two HA tags. Transfected HEK293 cells were
selected in Dulbecco modified Eagle’s medium (DMEM)
containing G418 (PAA Laboratories GmbH, Pasching,
Austria). Recombinant human H2A full-length and 4-
129 constructs were cloned in pET21a.
Antibodies and peptides
The following antibodies were used: H3K4me3 (Abcam
Inc., Cambridge, MA, USA), H3K9me3 (Upstate Labora-
tories Inc., New York, NY, USA), H3K20me3 (Upstate),
H2AK9Ac (Upstate), HA (12CA5) and Flag (Sigma Che-
mical Co., St Louis, MO, USA). The H2AR29me2 anti-
body was raised in rabbit against the peptide FPVGR
(me2a)VHRLLGC. Additional peptides used were the
unmethylated petide FPVGRVHRLLGC, the H2AR29
monomethylated peptide FPVGR(me1a)VHRLLGC, and
the H2AR3 di-methylated peptide SGR(me2a)GKAGGC.
Expression of recombinant H2A
Recombinant H2A constructs in pET21a were expressed
in the Rosetta Escherichia coli strain, and induced with
0.4 mol/l isopropyl b-D-1-thiogalactopyranoside (IPTG)
for 3 hours at 37°C. The preparation of inclusion bodies
was performed as described previously [27]. H2A was
dialysed against water for subsequent in vitro methyla-
tion assays.
Extraction of endogenous histones from cells
Cells from different cell lines and PRMT knockdown
cells were lysed in Ex-250 buffer (20 mmol/l HEPES pH
7.5, 250 mmol/l NaCl, 0.5 mmol/l MgCl2, 0.5% NP40)
for 15 minutes on ice. After centrifugation the pellet
was resuspended in 2% SDS and sonicated.
Protein purification
For the purification of H2A methylating enzymes,
approximately 8 × 10
9 HeLa S3 cells were collected. The
cell pellet was resuspended in hypotonic buffer (20
mmol/l HEPES pH 7.5, 20 mmol/l NaCl, 5 mmol/l
MgCl2). and incubated for 15 minutes on ice. After
homogenization, the cytoplasmic fraction was removed
by centrifugation. The nuclei were then lysed in hypo-
tonic buffer + 0.5% NP-40 detergent for 30 minutes,
and the soluble nuclear fraction was isolated by centrifu-
gation for 30 minutes. After pre-clearing, the extract
was adjusted to 100 mmol/l NaCl, and loaded onto a Q-
Sepharose column (Pharmacia, Uppsala). Elution was
performed with a stepwise increase of NaCl concentra-
tion, from 200 mmol/l to 1000 mmol/l NaCl. The H2A
activity-containing fraction was diluted to 50 mmol/l
NaCl, and loaded onto a diethylaminoethyl cellulose
(DEAE)-Sepharose column (Pharmacia, Uppsala). The
active fractions from the DEAE column were loaded
onto a heparin-Sepharose column (Pharmacia, Uppsala),
and factions from this column were dialysed against 20
mmol/l Tris pH 9 and 20 mmol/l NaCl. An in vitro
methylation assay was then performed. The 400 and 600
mmol/l fractions from the heparin-Sepharose column
were analysed by MS.
MS analysis of heparin-sepharose fractions
For details see Additional file 5.
Immunofluorescence
Stable cell lines expressing the different Flag-HA-
PRMTs were seeded onto poly-L-lysine-treated cover-
slips, fixed in 4% paraformaldehyde/1% sucrose for 15
minutes, and permeabilised in PBS + 0.6% Triton for 5
minutes. Incubation with rabbit Flag antibody (Sigma,
1:200) and secondary antibody (Fluor 488 anti-rabbit
IgG, Jackson Immunoresearch Laboratories, Inc., West
Grove, PA, USA) was performed in PBS/0.1% Tween/3%
BSA, then the cells were stained with 4’,6-diamidino-2-
phenylindole (DAPI) and mounted using mounting
medium (Vectashield; Vector Laboratories Inc., Burlin-
game, CA, USA). Image acquisition was performed with
aU Vc o n f o c a lm i c r o s c o p e( S P 2 ;L e i c aM i c r o s y s t e m s
Wetzlar GmbH, Wetzlar, Germany).
Immunoprecipitation of Flag-HA-PRMTs
Stable cell lines, expressing individual PRMTs, were
grown to confluency and lysed in Ex-250 buffer (20
mmol/l HEPES, pH 7.5, 250 mmol/l NaCl, 0.5 mmol/l
MgCl2, 0.5% NP40), followed by centrifugation and dilu-
tion to 150 mmol/l NaCl. After another centrifugation
step, HA antibodies (3 μgp e r2×1 0
7 cells) were added,
and incubated with 15 μl protein G sepharose. The
beads were washed twice with Ex-150 buffer (20 mmol/l
HEPES pH 7.5, 150 mmol/l NaCl, 0.5 mmol/l MgCl2,
0.5% NP40), and twice with PBS.
In vitro methylation assays
An aliquot (2 μg) of core histones, recombinant H2A,
MBP (Sigma) or glutathione S-transferase (GST)-GAR
were incubated with 10 μl of immunoprecipitated
PRMTs in PBS in a final volume of 30 μl. To this were
added 0.5 μCu S-adenoslyl methionine (Amersham
Laboratories, Amersham, Buckinghamshire, UK), then
the mixture was incubated for 1 hour at 30°C, and reac-
tions stopped by addition of loading buffer. Samples
were loaded onto a 18.7% polyacrylamide gel, blotted
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autoradiography.
Reverse transcription and real-time PCR
Total RNA was extracted from cells (Trizol reagent;
Invitrogen). cDNA was synthesised by using the MMLV
reverse transcriptase (Fermentas) and oligodT primer
according to the manufacturer’s instructions. One-tenth
of the cDNA was amplified by real-time PCR with SYBR
Green detection using a thermocycler with fluorescence
detection (7300; Applied Biosystems, Foster City, CA,
USA) and primers (see Additional file 6, table S1).
Western-blot quantification
ImageJ software was used for quantification of both
Ponceau-stained bands and western-blot signals. The
values corresponding to the western-blot signals were
normalized to the total amount of histones loaded, and
the ratios between the normalized signals in wild-type
and PRMT1/PRMT6 knockdown cells or PRMT6 over-
expressing cells, respectively, were calculated.
ChIP
Cells were crosslinked with 1% formaldehyde for 2 min-
utes at room temperature, and the reaction was stopped
by the addition of glycine to a final concentration of
0.25 mol/l. The fixed cells were rinsed twice with PBS,
and resuspended in 1 ml of Lysis Buffer 1 (50 mmol/l
Tris pH 8, 2 mmol/l EDTA pH 8, 0.1% NP40, 10% gly-
cerol) per 4 × 10
7 cells. After 10 minutes on ice the
lysate was centrifuged for 5 minutes at 500 g.T h e
nuclear pellet was resuspended in 1 ml of Lysis Buffer 2
(50 mmol/l Tris pH 8, 10 mmol/l EDTA pH 8, 0.1%
NP40, 0.2% SDS) and sonicated in a water-bath sonica-
tor (Diagenode, Liege), then centrifuged at 21000 g for
10 minutes. The cleared supernatant was pre-cleared
with 150 ml blocked beads for 1 hour, rotating at 4°C.
Chromatin was diluted 10 times in ChIP Dilution Buffer
(50 mmol/l Tris pH 8, 150 mmol/l NaCl, 0.25% NP40),
and then incubated overnight at 4°C with 4 mg of the
relevant antibody. The solution was then incubated for
2 hours with rotation at 4°C with 40 μl blocked beads to
recover the bound material. The beads were washed,
twice in 10 ml of Low Salt Buffer (20 mmol/l Tris pH 8,
150 mmol/l NaCl, 2 mmol/l EDTA pH 8, 0.25% NP40,
0.02% SDS), once with 10 ml of High Salt Buffer (20
mmol/l Tris pH 8, 250 mmol/l NaCl, 2 mmol/l EDTA
pH 8, 0.25% NP40, 0.02% SDS), and eluted by two 15-
minute incubations at 30°C with 125 μl elution buffer
(1% SDS, 0.1 mol/l NaHCO3). Chromatin was reverse-
crosslinked for 4 hours at 65°C in the presence of 10 U
RNase (Roche Applied Science, Indianapolis, IN, USA)
and 10 mg/ml proteinase K. DNA was extracted by phe-
nol-chloroform, and further purified with a commercial
kit (PCR Purification Kit; Qiagen Inc., Valencia, CA,
USA) according to the manufacturer’s instructions.
MS/MS analysis of methylated H2A
For details see Additional file 5, additional methods
Additional material
Additional file 1: Figure S1 - Identification of protein arginine
methyltransferase (PRMT)1 as a histone H2A methyltransferase,
using nanoscale liquid chromatography and mass spectrometry
(MS). The two fractions (numbers 4 and 6) from the heparin column
(Figure 1B) containing methyltransferase activity towards histone H2A 4-
129 were analysed by MS as described (see Additional file 6,
supplementary methods). Only proteins with two unique peptides
possessing a total Mascot score of >54 were considered to be significant,
and these were used for MS3 scoring in MSQuant software (http://
msquant.sourceforge.net). PRMT1 was found in both heparin fractions. IPI
and Uniprot accession numbers for PRMT1 are listed.
Additional file 2: Figure S2 - Purification and immunoprecipitation
of the different protein arginine methyltransferases (PRMTs). (A)
Immunoprecipitation of Flag-hemagglutinin (HA)-tagged PRMTs from
stable cell lines with HA-specific antibodies. Western blots with HA
antibodies are shown. Control for Figure 2A (B) Immunofluorescence
with Flag-specific antibody of stable cell lines expressing Flag-HA PRMTs
showing the localisation of the PRMTs. A merged view with 4’,6-
diamidino-2-phenylindole (DAPI) in blue and Flag signal in green is
shown on the right. (C) Histone methyltransferase assay of the
immunoprecipitated Flag-HA PRMTs using 2 μg myelin basic protein
(MBP) shows that HA-Flag PRMTs 1, 3, 5, 6, 7 and 8 are active. (Upper
panel) Autoradiography; (bottom panel) Coomassie stain (shown as
loading control).
Additional file 3: Figure S3 - Characterisation of the novel
H2AR29me2a antibody. (A) The indicated amounts of unmodified
H2AR29 peptide, monomethylated H2AR29 peptide, asymmetrically
dimethylated H2AR29 peptide (aa 25 to 34 of H2A) and asymmetrically
dimethylated H2AR3 peptide (aa 1 to 8) were spotted onto a membrane
and probed with the H2AR29me2a antibodies. This antibody specifically
recognised the immunising peptide in peptide dot blots, but not the
unmodified or the H2AR3 dimethylated peptide. (B) Full-length
recombinant H2A and equal amounts of acid-extracted histones (see
Coomassie staining below) from HeLa and Mcf7 cells were loaded onto
an SDS-PAGE gel and blotted with the H2AR29me2-specific antibody.
(Upper panel) In the western blot, the H2AR29me2 antibody specifically
recognised endogenous histones. (C) SDS-extracted histones were
loaded onto an SDS-PAGE gel. H2AR29me2 antibody was incubated with
no competitor, with 1 pmol unmethylated peptide, or with H2AR29me2
peptide. The methylated, but not the unmethylated peptide, competed
for the signal, confirming the specificity of the antibody. In addition, the
H3R17me2 peptide was not able to compete, showing that this antibody
is specific for H2AR29me2. (D) Total nuclear extract (NIH-3T3 cells) was
loaded onto an SDS-PAGE gel and (left panel) probed with H2AR29me2-
specific antibodies; (right panel) Ponceau stain. In this whole-cell extract,
the H2AR29me2 antibody specifically recognised H2A.
Additional file 4: Figure S4 - Identification of H2AR29me2 in vivo by
mass spectrometry (MS) analysis. (A) Overlay of the collisionally
activated dissociation (CAD) tandem MS (MS/MS) spectra (derived from
the endogenous H2A, isolated from Raji cells) of the specific tryptic (18
hour digest) peptide 22AGLQFPVGR(me2)29 (black) and the
corresponding synthetic peptide (supplementary methods) (red). Both
spectra are virtually identical, and allow the assignment of b and y ions
and the internal fragment ion PV+H+. (B) Trypsin cleavage
carboxyterminal to the dimethylated R29 in the histone H2A N-terminal
tail is inefficient, and requires extended incubation times. Acid-extracted
and gel-separated endogenous H2A was digested with trypsin for the
time points indicated. and subsequently analysed by nano liquid
chromatography (LC)-MS/MS. An extracted ion chromatogram (XIC;
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ratio (m/z) 486.77), which eluted between 40.5 to 40.9 minutes from the
C18 reverse-phase column, was derived from the total ion
chromatogram (TIC; illustrated in black). (C) The peak area under the
curve for the XIC of m/z 486.77 (mass was calculated and plotted against
the trypsin digestion time points as indicated. An increase of more than
10-fold in peptide ion intensity was seen in the 18 hour compared with
the 1 hour trypsin digest.
Additional file 5: Supplementary materials and methods.
Additional file 6: Table S1: Primers used in this study.
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